Perspective Therapeutics, Inc. (CATX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-11

Key Insights

Perspective Therapeutics announced Q1 2026 financial results on May 11, 2026, providing earnings disclosure and business updates to the market through a standard earnings release.
The company updated its corporate presentation and made it available on its investor relations website, suggesting active investor communication efforts during this reporting period.
The filing is relatively routine with only financial results and presentation materials disclosed; no material agreements, executive changes, or significant corporate events are reported that would substantially impact shareholder value.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-01

Perspective Therapeutics, Inc. has updated its corporate presentation, which could provide investors with new information about the company's latest developments and growth strategies.
The filing does not mention any material agreements, leadership changes, or earnings surprises, indicating a relatively routine update from the company.
Investors should review the updated corporate presentation for any insights into Perspective Therapeutics' pipeline, financial performance, or market opportunities.

Filed: 2026-03-16

Perspective Therapeutics, Inc. reported its financial results for the year ended December 31, 2025, providing investors with an update on the company's recent business activities.
The company posted an updated corporate presentation on its website, which investors can review to gain a better understanding of the company's strategic priorities and pipeline.
While the financial results and corporate presentation do not indicate any major or unexpected developments, the filing provides a regular update on the company's operations and ongoing initiatives.

Filed: 2026-02-03

Perspective Therapeutics, Inc. (CATX) successfully raised approximately $175 million through a public offering, which they plan to use to advance their clinical development pipeline and invest in manufacturing capabilities.
The company issued pre-funded warrants in addition to common stock, providing potential upside for investors if the warrants are exercised in the future.
The proceeds from the offering are expected to strengthen the company's financial position and support its strategic initiatives, though the specifics of how the funds will be used are not yet detailed.

Filed: 2026-02-02

Perspective Therapeutics, Inc. provided a corporate presentation with preliminary financial data for the year ended December 31, 2025, which has not been audited or reviewed by the company's independent accounting firm.
The company's actual results as of December 31, 2025 may differ from the preliminary financial data due to ongoing closing procedures and final adjustments.
Investors should wait for the company to report its audited financial results before drawing conclusions about the company's financial performance.

Filed: 2026-01-14

Perspective Therapeutics, Inc. has updated its corporate presentation, which may provide investors with new information on the company's strategic direction and product pipeline.
The filing does not indicate any material events or agreements, suggesting a routine regulatory filing without significant news.
As an NYSE American-listed company, Perspective Therapeutics is likely an emerging growth biopharmaceutical firm, which may carry higher risks and volatility for investors.

Filed: 2026-01-12

Perspective Therapeutics, Inc. has issued a press release on January 12, 2026 to provide business updates and strategic priorities.
The company's trading symbol on the NYSE American exchange is CATX, indicating it is a publicly traded entity.
The filing does not provide any financial or operational details, so the significance of the update is unclear from the information provided.

Filed: 2026-01-09

Perspective Therapeutics announced updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with neuroendocrine tumors, which will be presented at the 2026 ASCO GI Cancers Symposium.
The company's lead product candidate, [212Pb]VMT-α-NET, is being developed for the treatment of unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors.
The updated interim data release suggests the company is making progress in its clinical development program, which could potentially benefit investors if the data is positive.

Other reports for Perspective Therapeutics, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.